Join
Live feed
·
PRReleasevia Quantisnow
MannKind Corporation logo

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

ByQuantisnow·Wall Street's wire, on your screen.
MNKD· MannKind Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNKD (MannKind Corporation) and more on Quantisnow.